Ponatinib (for Ph+ ALL)
Treatment for Acute Lymphoid Leukemia
Typical Dosage: 15 mg to 45 mg orally once daily
Effectiveness
83%
Safety Score
45%
Clinical Trials
20
Participants
4K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
45
DangerousModerateSafe
Treatment Details
Dosage Range
15 mg to 45 mg orally once daily
Time to Effect
8-12 weeks (for molecular response)
Treatment Duration
Long-term (years, often combined with chemotherapy)
Evidence Quality
MODERATEConfidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$200,000
Monitoring:$20,000
Side Effect Mgmt:$30,000
Total Annual:$250,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$250,000/QALY
QALYs Gained
1.5
Outcome-Based Costs
Cost per Responder
$357,143
Cost per Remission
$454,545
Comparison vs Dasatinib
Cost Difference
+$65,000/year
More expensive
QALY Difference
+0.20 QALYs
Better outcomes
Dominance
No dominance
Ponatinib (for Ph+ ALL) Outcomes
for Acute Lymphoid Leukemia
Efficacy Outcomes
Overall Effectiveness
+83%
Response Rate
+70%
Remission Rate
+55%
Common Side Effects
Arterial occlusive events
+20%
Hypertension
+60%
Myelosuppression
+50%
Pancreatitis
+10%
Hepatotoxicity
+20%
Fluid retention
+40%
Active Clinical Trials
9 active trials recruiting for Ponatinib (for Ph+ ALL) in Acute Lymphoid Leukemia
Study in Adult Ph-positive ALL
NCT04688983NOT YET RECRUITINGPHASE2
180 participants
INTERVENTIONAL
Started: Jan 1, 2021
Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse
NCT04475731ACTIVE NOT RECRUITINGPHASE2
67 participants
INTERVENTIONAL
Ancona, Italy +21 more
Started: May 4, 2021
The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation
NCT04233346ACTIVE NOT RECRUITINGPHASE2
93 participants
INTERVENTIONAL
Hefei, China +13 more
Started: Jul 9, 2020
Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT
NCT06061094RECRUITINGPHASE2
220 participants
INTERVENTIONAL
Aachen, Germany +84 more
Started: Jul 14, 2023
Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)
NCT04747912RECRUITINGPHASE2
25 participants
INTERVENTIONAL
Chicago, United States
Started: Mar 2, 2021
Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL
NCT04722848ACTIVE NOT RECRUITINGPHASE3
236 participants
INTERVENTIONAL
Ascoli Piceno, Italy +14 more
Started: Sep 8, 2021
A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia
NCT03589326ACTIVE NOT RECRUITINGPHASE3
245 participants
INTERVENTIONAL
Birmingham, United States +91 more
Started: Oct 4, 2018
Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL
NCT06175702NOT YET RECRUITING
150 participants
OBSERVATIONAL
Started: Dec 25, 2023
Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma
NCT07224100NOT YET RECRUITINGPHASE2
33 participants
INTERVENTIONAL
Seattle, United States
Started: May 1, 2026
Completed Clinical Trials
5 completed trials for Ponatinib (for Ph+ ALL) in Acute Lymphoid Leukemia
Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)
NCT01207440COMPLETEDPHASE2
449 participants
INTERVENTIONAL
St Leonards, Australia +41 more
Started: Sep 30, 2010
Phase II Front-line Ponatinib in Adult Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia.
NCT01641107COMPLETEDPHASE2
44 participants
INTERVENTIONAL
Alessandria, Italy +41 more
Started: Dec 4, 2014
A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)
NCT01667133COMPLETEDPHASE1, PHASE2
35 participants
INTERVENTIONAL
Nagoya, Japan +10 more
Started: Aug 31, 2012
Comparative Evaluation of Results of Allogeneic Hematopoietic Stem Cells Versus Ponatinib in CML Patients Carrying a Mutation T315I
NCT02981784COMPLETED
184 participants
OBSERVATIONAL
Pierre-Bénite, France
Started: Jan 1, 2000
Iclusig® (Ponatinib) in Clinical Practice for the Treatment of Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in Belgium
NCT03678454COMPLETED
80 participants
OBSERVATIONAL
Antwerp, Belgium +18 more
Started: Feb 3, 2017
Showing 20 of 21 total trials